Fortress Biotech, Inc. Common Stock (FBIO) Stock
NASDAQ · FBIO
2.20
Fundamentals
Market cap
$76.04M
Price / Earnings ratio
0.7x
Price / Sales ratio
1.1x
Price / Book ratio
0.5x
Return on assets
54.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
NeutralFBIOAugust 12, 2026
MarketBeatNeutral
Fortress Biotech Q2 Earnings Call Highlights
FBIO

Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
NeutralFBIOFebruary 23, 2026
StocktwitsNeutral
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIO

Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
NeutralFBIOJanuary 13, 2026
StocktwitsNeutral
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIO
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

MarketBeat
Fortress Biotech Q2 Earnings Call Highlights
NeutralFBIOAugust 12, 2026
MarketBeatNeutral
Fortress Biotech Q2 Earnings Call Highlights
FBIO

Stocktwits
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
NeutralFBIOFebruary 23, 2026
StocktwitsNeutral
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
FBIO

Stocktwits
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
NeutralFBIOJanuary 13, 2026
StocktwitsNeutral
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease
FBIO
About Fortress Biotech, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees78
CEODr. Lindsay Allan Rosenwald M.D.
IPO DateNov 17, 2011
HeadquartersBay Harbor Islands, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Lindsay Allan Rosenwald M.D. | Executive Chairman, President & CEO | 1955 |
| Mr. David Jin | CFO & Head of Corporate Development | 1990 |
| Dr. Xiaoqin Lu M.D. | Chief Strategy Officer | 1975 |
| Mr. Michael S. Weiss Esq., J.D. | Executive Vice Chairman of Strategic Development & Director | 1966 |
Fundamentals
Valuation
Market cap$76.04M
Price-to-sales ratio1.11
Price-to-book value0.46
Price-earnings ratio0.70
Return on Equity153.00%
Return on Sales216.00%
Return on Assets54.00%
PEG ratio-0.10
Earnings Per Share
Earnings Per Share$3.26
Income Statement
Average volume301,034
EBITDA$149.41M
1 year high (52w)$4.53
1 year low (52w)$2.18
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.6 | +5.8 | -17.2 | -6.0 | ||||||||
| 2022 | -24.0 | -24.4 | -18.1 | -21.4 | -15.6 | +5.3 | +7.6 | +18.1 | -17.3 | -2.7 | -25.1 | -0.9 |
| 2023 | +40.0 | -14.6 | +9.3 | -5.3 | -31.3 | +0.9 | +0.5 | -38.2 | -27.3 | -61.9 | +17.9 | +38.7 |
| 2024 | -24.2 | +5.6 | -17.7 | -16.1 | +5.7 | -9.5 | +23.7 | -2.9 | -26.4 | +32.9 | +12.1 | -11.7 |
| 2025 | -14.2 | -14.2 | +2.6 | +14.9 | +8.0 | +1.1 | +1.6 | +42.5 | +24.2 | +0.0 | +15.6 | +34.6 |
| 2026 | -23.1 | +8.6 | -15.5 | -6.9 | +20.2 | +19.1 | +1.3 | -0.7 | -14.9 |



